Jazz Pharmaceuticals 以 1000 万美元的预付款、高达 8.7 亿美元的里程碑费用以及基于未来净销售额的特许权使用费收购了 Redx Pharma 的 KRAS 抑制剂项目。 Jazz Pharmaceuticals acquires Redx Pharma's KRAS inhibitor program for $10M upfront, up to $870M in milestones, and royalties based on future net sales.
Redx Pharma 已同意以 1000 万美元预付款向 Jazz Pharmaceuticals 出售其 KRAS 抑制剂，并有可能进一步支付高达 8.7 亿美元的里程碑付款。 Redx Pharma has agreed to sell its KRAS inhibitor to Jazz Pharmaceuticals for $10 million upfront, with the potential for further milestone payments up to $870 million. Jazz 将致力于 KRAS 抑制剂的临床开发、监管、制造和商业化活动，这可以为癌症患者提供新的治疗选择。 Jazz will work on clinical development, regulatory, manufacturing, and commercialisation activities for the KRAS inhibitors, which could provide new treatment options for cancer patients. 该交易旨在扩大 Jazz 的早期肿瘤产品线，并针对结直肠癌、胰腺癌和肺癌患者中普遍存在的 KRAS 突变。 The deal aims to expand Jazz's early-stage oncology pipeline and target KRAS mutations that are prevalent in colorectal, pancreatic, and lung cancer patients.